ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.

Senseonics Announces Equity Grants To Employees Under Inducement Plan

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 5, 2023 GMT

GERMANTOWN, Md.--(BUSINESS WIRE)--Jan 5, 2023--

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a).

On January 5, 2023, the Senseonics Compensation Committee granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 115,000 shares of the Company’s common stock as an inducement for such employees to join the Company. The options have an exercise price of $1.02 per share, which was the closing price of the Company’s common stock on the NYSE American on January 5, 2023. In each case, 25% of the shares underlying the options will vest on the first anniversary of the employee’s start date, with the remainder vesting in monthly installments over the subsequent three year period, in all cases contingent on such employee’s continued service with the Company at the applicable vesting date.

ADVERTISEMENT

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230105006038/en/

CONTACT: Senseonics Investor Contact

Philip Taylor

Investor Relations

415-937-5406

investors@senseonics.com

KEYWORD: UNITED STATES NORTH AMERICA MARYLAND

INDUSTRY KEYWORD: DIABETES HEALTH TECHNOLOGY HEALTH MEDICAL DEVICES

SOURCE: Senseonics Holdings, Inc.

Copyright Business Wire 2023.

PUB: 01/05/2023 05:58 PM/DISC: 01/05/2023 05:58 PM

http://www.businesswire.com/news/home/20230105006038/en